| Title: |
Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy |
| Authors: |
Khaitov, Musa; Shilovskiy, Igor; Valenta, Rudolf; Weber, Milena; Artem, Korneev; Tulaeva, Inna; Gattinger, Pia; Hage, Marianne van; Hofer, Gerhard; Konradsen, Jon; Keller, Walter; Akinfenwa, Oluwatoyin; Poroshina, Alina; Ilina, Nataliya; Fedenko, Elena; Elisyutina, Olga G.; Litovkina, Alla; Smolnikov, Evgenii V.; Nikonova, Alexandra; Rybalkin, Sergei; Aldobaev, Vladimir; Smirnov, Valeriy; Shershakova, Nadezhda; Petukhova, Olga; Kudlay, Dmitry; Shatilov, Artem; Timofeeva, Anastasia; Campana, Raffaela; Rabdano, Sevastyan; Trukhin, Victor; Udin, Sergey; Skvortsova, Veronica |
| Publisher Information: |
Authorea, Inc. |
| Publication Year: |
2023 |
| Collection: |
The Winnower (via CrossRef) |
| Description: |
Background: Respiratory birch pollen allergy and associated oral allergy syndrome affect more than 150 million people. IgE cross-sensitization to major birch pollen allergen Bet v 1 and pathogenesis-related (PR10) plant food allergens is responsible for the pollen-food allergy syndrome. Methods: We designed a recombinant protein, AB-PreS, consisting of non-allergenic peptides derived from the IgE binding sites of Bet v 1 and the cross-reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB-PreS was expressed in E. coli and purified by chromatography. The allergenic activity of AB-PreS was tested using sera and basophils from birch pollen patients allergic. The protective effect of AB-PreS was assessed by inhibition ELISA test using sera allergic patients and from immunized rabbits. Results: IgE-binding experiments and basophil activation test revealed the hypoallergenic nature of AB-PreS. IgG antibodies induced by 5 injections with AB-PreS inhibited allergic patients’ IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract-based vaccines. Additionally, immunization with AB-PreS induced HBV-specific antibodies potentially protecting the infection. Conclusion: The recombinant AB-PreS-based vaccine is hypoallergenic, safe and superior to currently registered allergen extract-based vaccines for the treatment of the birch pollen food allergy syndrome. |
| Document Type: |
other/unknown material |
| Language: |
unknown |
| DOI: |
10.22541/au.168205504.41863157/v1 |
| Availability: |
https://doi.org/10.22541/au.168205504.41863157/v1 |
| Accession Number: |
edsbas.D4E92F32 |
| Database: |
BASE |